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InteractionAbstract Bakumondo-to is a traditional herbal medicine. It has been widely used for the treatment
of chronic airway diseases. Recently, it was reported that several herbal medicines affected cyto-
chrome P450 (CYP). However, there is little information about the effects of Bakumondo-to on
CYP activities. In this study, we evaluated the effects of Bakumondo-to on CYP activities in rat
liver microsomes. Rats were orally treated twice a day with Bakumondo-to at doses of 2.0 g/kg
body weight/day for 4 days. CYP activities were determined in liver microsomes isolated from trea-
ted rats. CYP1A2, CYP2C, and CYP3A activities were measured using their specific substrates
[7-methoxyresorufin, 7-methoxy-4-(trifluoromethyl)-coumarin, and 7-benzyloxyquinoline, respec-
tively]. Bakumondo-to decreased CYP1A2 activity by 42.5 ± 7.8%, increased CYP2C activity by
158.0 ± 29.6%, and decreased CYP3A activity to 81.5 ± 7.8% of the control level. Activities were
expressed as percentages of the control.
Bakumondo-to induced CYP2C activity and decreased CYP1A2 activity; it may cause drug-
herbal interactions. It is suggested that combinations of Bakumondo-to and drugs that are metab-
olized by CYP1A2 and CYP2C should be carefully used in clinical settings.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As herbal medicines tend to have minor side effects and some-
times show remarkable efficacy (Ishohama, 2001), they are an
increasingly common form of complementary and alternative
therapy worldwide (Al-Ramahi et al., 2015). However, a wide
variety of herbal medical uses suggest the possibility for
co-administration with synthetic medications, and accordingly,
the potential of drug-herb interactions is high (Izzo and Ernst,
Effect of Bakumondo-to on cytochrome P450 activities in rat liver microsomes 1992001). Several studies concerning drug-herb interactions were
reported. St John’s wort (Hypericum perforatum), an herbal
antidepressant, is also well-known as a potent inducer of cyto-
chrome P450 (CYP) 3A (Roby et al., 2000; Wang et al., 2001).
In addition, analogs of catechin are inhibitors of CYPs, xan-
thine oxidase, and aldehyde oxidase (Tayama et al., 2011).
Shoseiryuto, another traditional herbal medication, demon-
strated CYP3A inhibitory activity in rat liver microsomes
(Makino et al., 2006). Ginkgo biloba extract increased CYP1A2
activity and produced effects on theophylline metabolism
(Tang et al., 2007). Their studies support findings that some
herbal medications or supplements have potentially harmful
side effects as well as adverse interactions with synthetic drugs.
Bakumondo-to, which is composed of Ophiopogon and
Pinelliae tubers, Jujube, Glycyrrhiza, and Ginseng, is a tradi-
tional herbal medicine. It has been widely used for the treat-
ment of chronic airway diseases, such as bronchitis,
bronchial asthma, and cough (Saika, 1991; Sasaki, 1993;
Irifune et al., 2011; Saruwatari et al., 2004). In addition,
Bakumondo-to is also used for Sjo¨gren’s syndrome patients
and affects their salivary secretion (Ohno et al., 1990). Clinical
use of Bakumondo-to has been increasing, and it is often co-
administrated with various medications, such as pranlukast,
zafirlukast, or theophylline. Therefore, it is possible that
Bakumondo-to interactions with synthetic drugs occur. Pran-
lukast is metabolized by CYP3A (Yoneda et al., 2009). Zafir-
lukast is metabolized by CYP2C9 and CYP3A4 (Dekhuijzen
and Koopmans, 2002), and montelukast is by CYP2C8
(Backman et al., 2016). Theophylline is metabolized by
CYP1A2 (Tjia et al., 1996). However, there is little information
about the effect of Bakumondo-to on these activities. In this
present study, we evaluated the effect of Bakumondo-to on
CYP1A2, CYP2C and CYP3A activities.
As for CYP1A2 activity, it was previously investigated in
human subjects. The mean activity of CYP1A2 tended to be
lower after dosing in 26 healthy humans with Bakumondo-to
for 7 days than that after dosing with placebo (Saruwatari
et al., 2004). However the effect of the protein expression by
Bakumondo-to is unclear. We also investigated the influence
of Bakumondo-to on CYP protein expression.
2. Material and methods
2.1. Chemicals
Bakumondo-to extract granules for ethical use were purchased
from Tsumura Co. (Tokyo, Japan). The reagents used were of
the highest commercial quality available. 7-Methoxy-4-(tri
fluoromethyl)-coumarin (MFC), 7-methoxyresorufin (MRF),
and 7-benzyloxyquinoline (BQ) were used as an external stan-
dard for quantification of CYP2C, CYP1A2, and CYP3A
activities and were purchased from BD Gentest (Woburn,
MA) (Stresser et al., 2002).
2.2. Animals
Jcl:Wistar male rats were obtained from CLEA Japan, Inc.
(Tokyo, Japan). The animals were housed in cages at 22 C
with a 12-h light/dark cycle and free access to tap water and
a standard pellet diet CE-2 (Clea Japan Co. Inc., Tokyo,
Japan). Rats, 6 week old, were randomized into two groups(n= 3 per group) receiving either water (control) or
Bakumondo-to (2.0 g/kg, p. o.) for 4 days. Their livers were
taken after the rats were euthanized. The animal protocol
was approved by the Animal Care and Use Committee of
Hiroshima International University.
2.3. Liver preparations
Livers were excised and homogenized in four volumes of
1.15% KCl. The microsomal fraction was obtained from the
homogenate by successive centrifugation at 9000g for 20 min
and 105,000g for 60 min. Liver microsomes were suspended
in potassium phosphate buffer. Protein concentrations were
determined by the method used by Lowry et al. with bovine
serum albumin as the standard protein (Lowry et al., 1951).
2.4. Assay for CYPs activities
The CYP activities were measured using the modified previous
methods (Sugihara et al., 2008; Stresser et al., 2002).
CYP2C activity was assayed using MFC as the substrate.
The reaction mixture containing liver microsomes (final con-
centration: 0.5 mg/mL), 100 lL of 5 mM NADPH, and
1840 lL of 0.1 M phosphate buffer was incubated at 37 C
for 15 min before 10 lL of 1 mM MFC was added to the incu-
bation mixture. The fluorescent products were detected by
monitoring fluorescence to determine the rates of MFC
O-demethylation (excitation: 410 nm and emission: 510 nm).
CYP1A2 activity was assayed using MRF as a substrate.
The reaction mixture containing liver microsomes (final con-
centration: 0.5 mg/mL), 100 lL of 5 mM NADPH, and
1840 lL of 0.1 M phosphate buffer was incubated at 37 C
for 3 min before 10 lL of 1 mM MR was added to the incuba-
tion mixture. CYP1A2 activity was measured in real time by
monitoring fluorescence to determine the rates of MR
O-demethylation (excitation: 550 nm and emission: 585 nm).
Rat CYP3A activity was assayed using BQ as the substrate.
The reaction mixture containing liver microsomes (final con-
centration: 0.5 mg/mL), 100 lL of 5 mM NADPH, and
1840 lL of 0.1 M phosphate buffer was incubated at 37 C
for 10 min before 10 lL of 1 mM BQ was added to the incuba-
tion mixture. CYP3A activity was measured in real time
by monitoring fluorescence to determine the rates of
7-hydroxyquinoline formation (excitation: 410 nm and emis-
sion: 510 nm).
2.5. Immunoblot analysis of CYPs
Expression levels of CYP proteins were determined by immu-
noblot analysis of liver microsomal proteins. The microsomal
proteins (50 lg) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on 10–20%
polyacrylamide gel (Atto Corporation, Tokyo, Japan), and
transferred to polyvinylidene difluoride (PVDF) membranes
by electroblotting. Membranes were then blocked with Block-
ing One (Nacalai Tesque, Inc., Kyoto, Japan) for 30 min and
probed with anti-rat CYP antibodies (1:2000) in 25 mM
Tris-buffered saline (pH 7.6) and 0.1% Tween 20 for 24 h.
The membranes were washed and antibody binding
was detected with horseradish peroxidase-conjugated goat
200 M. Yasuhara et al.anti-rabbit IgG (1:1000), followed by development with
Chemi-Lumi One L (Nacalai Tesque, Inc., Kyoto, Japan).
2.6. Statistical analysis
Data are presented as mean ± standard deviation (S.D.).
The statistical significance of differences was evaluated using
F-test. If the F values were significant, the student t-test in
homoscedasticity or Welch-t test in heteroscedasticity was
performed. P < 0.05 was considered significant.3. Results
3.1. Effects of Bakumondo-to on CYP activity in rat liver
microsomes
As shown in Fig. 1, it was observed that the MRF
O-demethylation conversion (indicating CYP1A2 activity in
the Bakumondo-to groups) showed a decrease of 42.5 ±
7.8% (% of control). The CYP1A2 activity was significantly
inhibited by Bakumondo-to. MFC O-demethylation (indicat-
ing CYP2C activity) increased by 158.0 ± 29.6%. The activity
was significantly increased compared with that of the control.
7-BQ hydroxylation (indicating CYP3A activity) was 81.5
± 7.8% and was not significantly different from the control.
3.2. Effects of Bakumondo-to on CYP protein expression in rat
liver microsomes
We evaluated the effect on CYP protein expression by
Bakumondo-to (Fig. 2).Figure 1 Changes of liver CYPs activity in rats treated with Bakumo
Each CYPs activity was measured in real time by monitoring fluoresce
bar represents mean ± S.D. of three experiments.SDS–PAGE immunoblot analysis with anti-rat CYP1A2
antibodies showed that there were no significant changes in
the expression of CYP1A2 proteins between control subjects
and Bakumondo-to administrated subjects. In contrast,
CYP2C protein expression of Bakumondo-to subjects
increased to 288.9% compared with that of the control sub-
jects. There were no significant changes in the protein expres-
sion of CYP3A.
4. Discussion
Bakumondo-to, administered for chronic airway diseases, is a
herbal medicine. In general, herbal compounds, such as
St John’s wort and catechins, inhibit enzyme activities. How-
ever, it was unclear whether CYP activity was affected by
Bakumondo-to. The aim of this study was to evaluate the
effects of Bakumondo-to on CYP activity. We also examined
the protein expression.
CYP3A is a major metabolic enzyme in the human liver.
The enzyme metabolizes many kinds of drugs, such as midazo-
lam, felodipine, lovastatin, and triazolam. Therefore, we eval-
uated the effects of Bakumondo-to on CYP3A. In this study, it
was observed that Bakumondo-to had no effect on CYP3A by
in rat liver microsomes. Therefore, Bakumondo-to may not
interact with other drugs via CYP3A in clinical treatment.
CYP1A2 is a metabolic enzyme for theophylline, tizanidine,
and caffeine. In several cases, Bakumondo-to was co-
administrated with theophylline for airway inflammation and
chronic bronchitis treatment. Saruwatari et al. (2004) reported
that Bakumondo-to tended to inhibit the CYP1A2 activity
after 7 days in an in vivo human study. In our study, it was
observed that Bakumondo-to significantly inhibited CYP1A2ndo-to. (A) MRF: CYP1A2, (B) MFC: CYP2C, (C) BQ: CYP3A.
nce to determine the rates of moderate substrate formation. Each
Figure 2 Analysis of the expression and the bands density of liver CYPs protein in rats treated with Bakumondo-to by Western
immunoblotting with (A) anti-CYP1A2 antibody, (B) anti-CYP2C9 antibody, and (C) anti-CYP3A antibody. Each point represents the
mean ± S.D. of three experiments.
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with that of the control. It suggested that the inhibition of
CYP1A2 activities by Bakumondo-to is independent of protein
expression. Taking our and Saruwatari’s study data into
account, Bakumondo-to may change the affinity of CYP1A2.
Chang reported that Ginseng root extract, one of the compo-
nents of Bakumondo-to, inhibited CYP1A2 activity (Chang
et al., 2002). However, the inhibitory components and mecha-
nisms are still unknown and need to be clarified.
CYP2C is approximately 25% of P450 in human liver
microsomes (Imaoka et al., 1996). It is reported that CYP2C
is the key enzyme for the metabolism of zafirlukast,
montelukast, omeprazole, and phenytoin (Dekhuijzen and
Koopmans, 2002; Karonen et al., 2012). Zafirlukast or
montelukast, a leukotriene receptor antagonist, is used for
the treatment of asthma and allergic rhinitis. Bakumondo-to
is co-administrated with zafirlukast or montelukast in several
cases. Therefore, we also examined the effect of Bakumondo-to on CYP2C. The activities were increased by 158%, and
the density of CYP2C bands were increased by 288% com-
pared with that of the control groups. The data suggest that
the increased activities depend on the induced protein expres-
sion. Only 4 days of treatment caused CYP2C induction. If
Bakumondo-to is administered for long periods in clinical
situations caution should be taken to prevent drug-herbal
interactions via CYP2C.5. Conclusion
In conclusion, Bakumondo-to induced CYP2C activities, fol-
lowed by protein expression. In contrast, Bakumondo-to
decreased CYP1A2 activity which may be caused by the
drug-herbal interaction. Therefore it is advised to carefully
use combinations of Bakumondo-to with drugs that are
metabolized by CYP1A2 and CYP2C in clinical settings.
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